EMA to be given more power and independence in handling COVID-19 pandemic and future health emergencies. Negotiations between member states and European Parliament are due to begin
Head of EU pharma trade body says waiver would ‘open the door to counterfeit vaccines’ and kill incentives to tackle dangerous virus variants. ‘Who will make the vaccine next time?’ one pharma chief asks
The Innovative Medicines Initiative project ZAPI has put in place a new pan-virus methodology for ramping up the production of new vaccines in the next crisis
As COVID-19 shows, older people are particularly vulnerable to infectious diseases. IMI’s VITAL project is studying vaccines and immunity in older adults, to figure out the best strategies to keep people healthier for longer.
As the problem of COVID-19 vaccines supplies so potently illustrates, it is time to rethink the EU’s pandemic preparedness strategy. More support is needed for late stage clinical development and large scale manufacturing
Amid pressure to speed up vaccination programmes some member states are starting to go their own way on securing doses. The EU’s head vaccine official says no country can jump the queue
Politicians accuse manufacturers of lack of transparency over multi-million deals with Brussels, and raise concerns over exemptions from legal action in case vaccines go wrong
The Innovative Health Initiative will see the scope of joint research between industry, academics and SMEs expand beyond pharmaceuticals, to include medical technology, biotech, digital health and vaccines
Receive the Funding Newswire [full access requires a subscription] each Tuesday, our Policy Bulletin each Thursday, and the fortnightly R&D Express, tracking reforms and investments in central and eastern Europe.
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.